• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does PROM vs Intact Membranes in Previous Pregnancy Impact Success of Pessary or Progesterone in Future Pregnancy with Short Cervix?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Broad classification of preterm birth
    • Iatrogenic preterm birth
    • Spontaneous preterm birth (sPTB)
      • Spontaneous preterm labor (PTL) with intact membranes (IM)
      • Preterm prelabor rupture of membranes (PPROM)
  • Care et al. (Ultrasound in Obstetrics and Gynecology, 2018) investigated whether the above classification of a previous sPTB alters the efficacy of pessary or vaginal progesterone in subsequent pregnancies with short cervix

METHODS:

  • Retrospective cohort study
    • Multicenter (2008-2015)
  • Participants
    • Pregnancy with short cervix and a history of sPTB
    • Otherwise asymptomatic | Singleton
    • No congenital anomalies
  • Classification
    • PTL-IM: ≤34 weeks
    • PPROM: ≤34 weeks
  • Definition of ‘short cervix’
    • Single measurement of ≤ 25 mm or
    • < 3rd centile for gestational age
  • Treatments for primary PTB prevention
    • Arabin pessary or
    • Vaginal progesterone: 200 mg at night
  • Primary outcome: Gestational age at delivery with exclusion of the following
    • Additional cerclage
    • Swapped therapies
    • Additional treatments
  • Secondary outcomes: All women included
  • Analysis
    • Linear regression analysis used based on (1) treatment type (2) cervical length (3) previous sPTB classification

RESULTS:

  • 170 women were treated with pessary | 88 were treated with vaginal progesterone
  • Women with history of PPROM delivered earlier (35 weeks) than PTL-IM (38 weeks); P ≤ 0.001
  • Treated with pessary: sPTB <34 weeks rate was
    • PTL-IM: 16%
    • PPROM: 55%
  • Treated with vaginal progesterone: sPTB <34 weeks was
    • PTL-IM: 15%
    • PPROM: 21%
    • No difference in duration of pregnancy in this group regardless of PTL-IM or PPROM
  • Overall, Pessary treatment for women with previous PPROM resulted in greatest percentage of sPTB <34 weeks (P < 0.0001)
  • Independent factors affecting early gestational age at birth
    • PPROM history (P < 0.0001)
    • Combination of PPROM history and treatment type (P= 0.0003)
    • Cervical length (P=0.0004)

CONCLUSION:

  • Cervical pessary appears to be least efficacious therapy for women with short cervix, history of sPTB and PPROM
  • Authors conclude that
    • Classification system of prior sPTB may be helpful in determining management in subsequent pregnancies
    • Previous history may account for conflicting results regarding benefit of pessary for prevention of sPTB in the setting of short cervix
    • Prospective studies would be necessary prior to change in clinical practice

Learn More – Primary Sources:

Should phenotype of previous preterm birth influence management of women with short cervix in subsequent pregnancy? Comparison of vaginal progesterone and Arabin pessary

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Progesterone or Cerclage in Preterm Prevention in Women with Previous Preterm Birth and Short Cervix?
Does Vaginal Progesterone Improve Birth Outcomes for Mothers with Short Cervix?
Does Cervical Pessary Benefit Women at risk for Preterm Birth due to Short Cervix?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site